SCHEMBL3011697

SCHEMBL3011697

CC(C)(C)c1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)cc4)cs3)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.39
TP53 P04637 1/20 0.38
MAPT P10636 7/20 0.37
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
HTR2A P28223 2/20 0.35
DRD2 P14416 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
PTGER2 P43116 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021340 0.93 MAPT (0.35) HSD11B1TP53MAPTLMNASMN1; SMN2
SCHEMBL3017031 0.92 MAPT (0.42) MAPTLMNASMN1; SMN2NPSR1HTR2A
SCHEMBL3002256 0.91 ACHE (0.34) HSD11B1TP53LMNASMN1; SMN2NPSR1
SCHEMBL3014372 0.91 GBA1 (0.41) HSD11B1MAPTLMNASMN1; SMN2NPSR1
SCHEMBL3012703 0.90 HTR2A (0.41) HSD11B1TP53MAPTLMNASMN1; SMN2
SCHEMBL3014922 0.90 LMNA (0.37) HSD11B1TP53MAPTLMNASMN1; SMN2
SCHEMBL3015108 0.90 AOC3 (0.35) HSD11B1HTR2AHTR2CKCNH2ACHE
SCHEMBL3015929 0.89 TRPV1 (0.36) HSD11B1TP53MAPTLMNASMN1; SMN2
SCHEMBL3001231 0.89 MAPT (0.42) MAPTLMNASMN1; SMN2NPSR1ALDH1A1
SCHEMBL3018372 0.89 MAPT (0.39) TP53MAPTLMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD11B1 1034/4885TP53 2880/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.